Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 18381960)

  • 1. Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11.
    Oliver PG; LoBuglio AF; Zinn KR; Kim H; Nan L; Zhou T; Wang W; Buchsbaum DJ
    Clin Cancer Res; 2008 Apr; 14(7):2180-9. PubMed ID: 18381960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model.
    Buchsbaum DJ; Zhou T; Grizzle WE; Oliver PG; Hammond CJ; Zhang S; Carpenter M; LoBuglio AF
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3731-41. PubMed ID: 14506165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The synergistic effects of low-dose irinotecan and TRAIL on TRAIL-resistant HT-29 colon carcinoma in vitro and in vivo.
    Zhu H; Zhao F; Yu S; He J; Deng L; Yi C; Huang Y
    Int J Mol Med; 2012 Nov; 30(5):1087-94. PubMed ID: 22922573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination treatment with TRA-8 anti death receptor 5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancer.
    DeRosier LC; Buchsbaum DJ; Oliver PG; Huang ZQ; Sellers JC; Grizzle WE; Wang W; Zhou T; Zinn KR; Long JW; Vickers SM
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5535s-5543s. PubMed ID: 17875786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model.
    Straughn JM; Oliver PG; Zhou T; Wang W; Alvarez RD; Grizzle WE; Buchsbaum DJ
    Gynecol Oncol; 2006 Apr; 101(1):46-54. PubMed ID: 16271751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice.
    Naka T; Sugamura K; Hylander BL; Widmer MB; Rustum YM; Repasky EA
    Cancer Res; 2002 Oct; 62(20):5800-6. PubMed ID: 12384541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of anti-DR5 and chemotherapy on basal-like breast cancer.
    Oliver PG; LoBuglio AF; Zhou T; Forero A; Kim H; Zinn KR; Zhai G; Li Y; Lee CH; Buchsbaum DJ
    Breast Cancer Res Treat; 2012 Jun; 133(2):417-26. PubMed ID: 21901385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The sirtuin inhibitor tenovin-6 upregulates death receptor 5 and enhances cytotoxic effects of 5-fluorouracil and oxaliplatin in colon cancer cells.
    Ueno T; Endo S; Saito R; Hirose M; Hirai S; Suzuki H; Yamato K; Hyodo I
    Oncol Res; 2013; 21(3):155-64. PubMed ID: 24512730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced apoptosis following treatment with TRA-8 anti-human DR5 monoclonal antibody and overexpression of exogenous Bax in human glioma cells.
    Kaliberov S; Stackhouse MA; Kaliberova L; Zhou T; Buchsbaum DJ
    Gene Ther; 2004 Apr; 11(8):658-67. PubMed ID: 14973547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CPT-11 in human colon-cancer cell lines and xenografts: characterization of cellular sensitivity determinants.
    Jansen WJ; Zwart B; Hulscher ST; Giaccone G; Pinedo HM; Boven E
    Int J Cancer; 1997 Jan; 70(3):335-40. PubMed ID: 9033637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergism of CPT-11 and Apo2L/TRAIL against two differentially sensitive human colon tumor xenografts.
    Sugamura K; Gibbs JF; Belicha-Villanueva A; Andrews C; Repasky EA; Hylander BL
    Oncology; 2008; 74(3-4):188-97. PubMed ID: 18714167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11.
    Ray S; Almasan A
    Cancer Res; 2003 Aug; 63(15):4713-23. PubMed ID: 12907654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-tumor activity of an anti-DR5 monoclonal antibody, TRA-8, in combination with taxane/platinum-based chemotherapy in an ovarian cancer model.
    Bevis KS; McNally LR; Sellers JC; Della Manna D; Londoño Joshi A; Amm H; Straughn JM; Buchsbaum DJ
    Gynecol Oncol; 2011 Apr; 121(1):193-9. PubMed ID: 21211830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
    Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with gemcitabine and TRA-8 anti-death receptor-5 mAb reduces pancreatic adenocarcinoma cell viability in vitro and growth in vivo.
    DeRosier LC; Huang ZQ; Sellers JC; Buchsbaum DJ; Vickers SM
    J Gastrointest Surg; 2006 Nov; 10(9):1291-300; discussion 1300. PubMed ID: 17114015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual combination therapy targeting DR5 and EMMPRIN in pancreatic adenocarcinoma.
    Kim H; Zhai G; Samuel SL; Rigell CJ; Umphrey HR; Rana S; Stockard CR; Fineberg NS; Zinn KR
    Mol Cancer Ther; 2012 Feb; 11(2):405-15. PubMed ID: 22203731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irinotecan overcomes the resistance to 5-fluorouracil in human colon cancer xenografts by down-regulation of intratumoral thymidylate synthase.
    Fukushima M; Sakamoto K; Ohshimo H; Nakagawa F; Taguchi T
    Oncol Rep; 2010 Oct; 24(4):835-42. PubMed ID: 20811661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delivery of tumor-homing TRAIL sensitizer with long-acting TRAIL as a therapy for TRAIL-resistant tumors.
    Oh Y; Swierczewska M; Kim TH; Lim SM; Eom HN; Park JH; Na DH; Kim K; Lee KC; Pomper MG; Lee S
    J Control Release; 2015 Dec; 220(Pt B):671-81. PubMed ID: 26381901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts.
    Motwani M; Jung C; Sirotnak FM; She Y; Shah MA; Gonen M; Schwartz GK
    Clin Cancer Res; 2001 Dec; 7(12):4209-19. PubMed ID: 11751522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38.
    LaBonte MJ; Manegold PC; Wilson PM; Fazzone W; Louie SG; Lenz HJ; Ladner RD
    Int J Cancer; 2009 Dec; 125(12):2957-69. PubMed ID: 19536776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.